Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opexa Pharmaceuticals Inc.

Division of Acer Therapeutics Inc.
www.opexapharmaceuticals.com

Latest From Opexa Pharmaceuticals Inc.

Opexa Pharmaceuticals Inc.

Opexa Pharmaceuticals was founded in February 2001 to develop therapeutic vaccines for autoimmune diseases. Based on techniques designed by co-founder Jingwu Zhang of Baylor College of Medicine, its first product is a vaccine comprised of autologous myelin-reactive T-cells that stimulate the immune response of patients with multiple sclerosis. The selectivity of the process enables greater efficacy with fewer side effects than existing therapies for MS.
BioPharmaceutical Business Strategies

New Approaches to Treating Autoimmune Diseases

In the past few years, new classes of biologics have revolutionized treatment of autoimmune diseases, especially multiple sclerosis, rheumatoid arthritis, psoriasis, and asthma. Biologics tend to be most effective because they work on specific targets and impact the underlying causes of disease. In addition to new biologics, a number of companies and academic researchers are looking at expanding applications for certain cancer drugs to autoimmune diseases. The rationale behind this is straightforward: both diseases have inflammatory effects and require cytotoxic approaches. However, for all the difficulties scientists have had in understanding cancer, they've had even more in trying to figure out autoimmune diseases. Autoimmune diseases tend to have systemic effects and thus it's hard to pinpoint a single site of disease.
BioPharmaceutical Business Strategies

Start-Up Previews (9/03)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Therapeutics for Autoimmune Disorders, features profiles of Bayhill Therapeutics Inc., Can-Fite Biopharma Ltd. and Opexa Pharmaceuticals Inc. Plus these Start-Ups across Health Care: Bionaut Pharmaceuticals Inc., SkinMedica Inc., Vivant Medical Inc. and ZelleRx Corp.

BCM Technologies Inc.

BCM Technologies, the for-profit venture arm of the Baylor College of Medicine, has a hands-on approach to university technology transfer has served both the medical school and external investors well. First round investors in BCMT's first 14 spin-offs earned a 35% internal rate of return.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Acer Therapeutics Inc.
  • Senior Management
  • Michael Redman, Pres. & CEO
    J. Donald Payne, CFO
    Mitzi Martinez-Montgomery, PhD, VP, Dev.
  • Contact Info
  • Opexa Pharmaceuticals Inc.
    Phone: (281) 775-0600
    835 Greens Pkwy.
    Ste. 150
    Houston, TX 77067
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register